Automated Pulverisette 2 Mortar Mill grinds in double quick time

Published: 22-Feb-2010
Manufacturing

The Automated Pulverisette 2 Mortar Mill from Fritsch is essential for grinding pharmaceutical tablets, pastilles or dragees for further analysis in double quick time.

The Automated Pulverisette 2 Mortar Mill from Fritsch is essential for grinding pharmaceutical tablets, pastilles or dragees for further analysis in double quick time. Reproducible, loss-free fine grinding is achieved through pressure and friction with zero heat generation through to the sample. The illuminated grinding chamber also has a digital timer for ease of use. A wide choice of interchangeable grinding sets is available, which are both easy to remove and clean. Available from: C. Gerhardt UK Ltd, the exclusive Fritsch distributor for UK and Ireland. Visit www.cgerhardt.com or telephone 01280 706772 for further information.
See more

You may also like

Manufacturing

Innovation in generics: increased efficiency through peptide API synthesis expertise

Read more
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  3. Memel Biotech and Therabest collaborate to develop exosome-based cell therapies The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
  4. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
  5. How a circular economy can benefit pharma manufacturers Implementing a circular economy can be beneficial for the planet and your business, if you play your cards right

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Innovation in generics: increased efficiency through peptide API synthesis expertise

Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
Manufacturing

For easy transition from glass to plastic accessories - BOLA components with GL threads

The GL thread is the most common thread on lab equipment made of glass. Available from Labtex in the UK, BOLA offers a modular construction system with many different components with GL threads
Distribution

ChargePoint invest in a single-use manufacturing facility to expand product line

The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Manufacturing

Optimising RNA production for faster and cheaper pharmaceutical manufacturing

RNA production can be a lengthy and complex process, but the Ntensify platform could change this by diminishing development times, decreasing production costs and allowing the avoidance of scaling issues
Manufacturing

Memel Biotech and Therabest collaborate to develop exosome-based cell therapies

The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Manufacturing

INEOS Nitriles launches INVIREO - the first bio-based acetonitrile

The company has released INVIERO, an acetonitrile capable of significantly reducing the carbon footprint of manufacturing processes
Manufacturing

Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities

Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Subscribe now